In a report released today, Matt Hewitt from Craig-Hallum maintained a Buy rating on OmniAb (OABI – Research Report). The company’s shares opened today at $5.46.
Hewitt covers the Healthcare sector, focusing on stocks such as Codexis, Inotiv, and Apyx Medical. According to TipRanks, Hewitt has an average return of 2.8% and a 45.62% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for OmniAb with a $9.67 average price target, a 77.11% upside from current levels. In a report released on March 22, Benchmark Co. also maintained a Buy rating on the stock with a $8.00 price target.
OABI market cap is currently $596.3M and has a P/E ratio of -10.11.
Based on the recent corporate insider activity of 28 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of OABI in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
OmniAb (OABI) Company Description:
Avista Public Acquisition Corp II is a blank check company.
